GlassScriptPhysician profile
Douglas R Davis
NPI 1386056083
$100,284.24
in general payments reported to CMS, 2019-2025
42 companies · $6,914 in 2025
The $6,914 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $7,888 · 2021: $8,963 · 2022: $33K · 2023: $18K · 2024: $25K · 2025: $6,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $6,474 · Consulting Fee: $2,758 · Travel and Lodging: $1,779 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,475.00 |
| Food and Beverage | $6,473.65 |
| Consulting Fee | $2,758.00 |
| Travel and Lodging | $1,778.54 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $77,428.34 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Allergan, INC. | $8,820.23 | 2019-2022 | |
| Pfizer INC. | $4,099.52 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,849.14 | 2021-2023 | |
| Celgene Corporation | $2,029.22 | 2022-2025 | Zeposia |
| Eisai INC. | $437.24 | 2023-2025 | |
| Genentech USA, INC. | $350.56 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Lilly USA, LLC | $343.96 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Kyowa Kirin, INC. | $339.63 | 2022-2024 | Nourianz |
| Acadia Pharmaceuticals INC | $330.21 | 2022-2025 | Nuplazid |
| Genzyme Corporation | $318.49 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $299.16 | 2021 | |
| Biogen, INC. | $298.55 | 2020-2025 | Tysabri, Vumerity, Avonex |
| Mdd US Operations, LLC | $265.63 | 2022-2024 | Apokyn, Apokyn, Gocovri |
| Neurocrine Biosciences, INC. | $232.64 | 2022-2025 | Ingrezza, Ongentys |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.